Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GSK American Depositary Shares Representing 2 Ordinary Shares GSK

Consumer Cyclical
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also... see more

Recent & Breaking News (NYSE:GSK)

Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

Business Wire March 16, 2024

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

Business Wire March 7, 2024

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

GlobeNewswire February 8, 2024

23andMe Reports Third Quarter Fiscal 2024 Financial Results

GlobeNewswire February 7, 2024

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

GlobeNewswire February 7, 2024

GSK's RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

Business Wire February 6, 2024

Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen's Cell-Free DNA Production Technology

Business Wire January 24, 2024

GSK Enters Agreement to Acquire Aiolos Bio

Business Wire January 9, 2024

GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity

Business Wire December 12, 2023

GSK and Queer Eye's Thom Filicia Partner on Blood Cancer Awareness Initiative

Business Wire November 13, 2023

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

GlobeNewswire October 30, 2023

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

GlobeNewswire October 27, 2023

New Data for AREXVY, GSK's RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

Business Wire October 25, 2023

Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

Business Wire September 15, 2023

GSK and Earvin "Magic" Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations

Business Wire September 5, 2023

GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies

Business Wire August 17, 2023

Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Business Wire July 31, 2023

GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US

Business Wire July 13, 2023

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

Canada NewsWire June 28, 2023

US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making

Business Wire June 21, 2023